Latest Sipuleucel-T Stories
SEATTLE, Sept. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark, chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group, has resigned from the company's Board of Directors.
LOS ANGELES, Sept. 13 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) with a twelve month target price of $4.40.
RESEARCH TRIANGLE PARK, NC, Aug.
SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009.
SEATTLE, July 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGEÂ® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC).
WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double from nearly $4 billion in 2009 to $8.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
SEATTLE, July 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Tuesday, August 3, 2010 at 4:30 p.m. ET to review second quarter financial results.
SEATTLE, June 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced that the Centers for Medicare and Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) of PROVENGEÂ® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).
BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVaxÂ® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr.
- To fire mitraille at.